Colonic mucosal expression of heat-shock proteins may have a potential prognostic value in ulcerative colitis

Arab Journal of Gastroenterology

Volumn 16, Issue 1, 2015, Pages 20-24

  Abou El Azm, Abdel Raouf ^a   Yousef, Mohamed ^a   Kobtan, Abdelrahman ^a   Awad, Aymen ^a   Elkassas, Galal ^a   Elfert, Asem ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Colonic dysplasia; Heat shock proteins; HSP70; HSP90; Ulcerative colitis

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESALAZINE; BIOLOGICAL MARKER;

ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DYSPLASIA; ENDOSCOPIC BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IRRITABLE COLON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; ULCERATIVE COLITIS; ADULT; COHORT ANALYSIS; COLON; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PRECANCER; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; BIOPSY, NEEDLE; COHORT STUDIES; COLITIS, ULCERATIVE; COLON; DISEASE PROGRESSION; FEMALE; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84938961218     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2015.02.005     Document Type: Article

References (23)

1. Schirbel A, Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis 2010;11:266-76.
2. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012;107(11):1684-92.
3. Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31(3-4):336-44.
4. Tomasello G, Bellavia M, Palumbo VD, et al. From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases? Ann Ital Chir 2011;82:361-8.
5. Tomasello G, Sciumé C, Rappa F, et al. HSP10, HSP70, and HSP90 immunohistochemical levels change in ulcerative colitis after therapy. Eur J Histochem 2011;55:210-4.
6. Rappa F, Farina F, Zummo G, et al. HSP-molecular chaperones in cancer biogenesis and tumor therapy: an overview. Anticancer Res 2012;32:5139-50.
7. Weigl E, Kopeček P, Raška M, et al. Heat shock proteins in immune reactions. Folia Microbiol 1999;44:561-6.
8. Rutherford SL, Lindquist S. HSP90 as a capacitor for morphological evolution. Nature 1998;396:336-42.
9. Basu S, Binder RJ, Ramalingam T, et al. CD91 is a common receptor for heat shock proteins gp96, HSP90, HSP70, and calreticulin. Immunity 2001;14:303-13.
10. Quintana FJ, Cohen IR. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J Immunol 2005;175:2777-82.
11. Hu SE, Zhu XR, Triggs JR, et al. Inflammation-induced, 30UTR-dependent translational inhibition of HSP70 mRNA impairs intestinal homeostasis. Am J Physiol Gastrointest Liver Physiol 2009;296(5):G1003-11.
12. Liedel JL, Guo Y, Yu Y, et al. Mother's milk-induced HSP70 expression preserves intestinal epithelial barrier function in an immature rat pup model. Pediatr Res 2011;69(5):395-400.
13. Ludwig D, Stahl M, Ibrahim ME, et al. Enhanced intestinal expression of heat shock protein 70 in patients with inflammatory bowel diseases. Dig Dis Sci 1999;44(7):1440-7.
14. Maynard CL, Elson CO, Hatton RD, et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012;489(7415):231-41.
15. Musch MW, Sugi K, Straus D, et al. Heat shock protein 72 protects against oxidant-induced injury of barrier function of human colonic epithelial Caco2/bbe cells. Gastroenterology 1999;117(1):115-22.
16. Shroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-ASA therapy for mildly to moderately active ulcerative colitis. A randomized study. NEJM 1987;24213(26):1625-9.
17. Geboes K, Riddell R, Öst A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.
18. Riddell RH, Goldman H, RansohoffDF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14(11):931-68.
19. Suzuki M, Inoue Y, Tezuka T, et al. Local complications of the intestinal tract in patients with ulcerative colitis. Nihon Rinsho 1999;57(11):2527-31 (abstract).
20. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
21. Feagins LA, Melton SD, Iqbal R, et al. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013 Jun;19(7):1477-82.
22. Schulz R, Moll UM. Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer. Curr Opin Oncol 2014;26(1):108-13.
23. Tao Y, Hart J, Lichtenstein L, et al. Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer. Carcinogenesis 2009;30(1):175-82.